Caris Life Sciences (CAI) Up +59.8% in 30 Days on Record Q2 Results
Key Takeaways
- CAI shares closed at $24.58, up about 59.8% from $15.38 roughly 30 calendar days earlier, marking a sharp re-rating after a prolonged drawdown.
- The rally was driven by record second-quarter 2026 results reported on August 5, including revenue of $263.7 million, up 45% year over year, and a full-year guidance increase.
- Molecular profiling services revenue rose 55% to $252.3 million, supported by record clinical case volume of approximately 59,200, up 18% year over year.
- The commercial launch of Caris Detect, a multi-cancer early detection blood test, and new assays strengthened the growth narrative.
- The stock remains well below its 52-week high of $42.50, and its quarterly trend reflects a recovery from a mid-2026 low.
Company Overview and Market Position
Caris Life Sciences, Inc. operates as an AI-driven “TechBio” company focused on precision medicine in oncology. It performs whole exome and whole transcriptome sequencing on every patient sample, building a proprietary clinico-genomic database of more than 1.13 million profiled patients that supports its diagnostic tools and product development.
Revenue comes primarily from molecular profiling services, which represented roughly 96% of total revenue in the second quarter of 2026, with smaller contributions from pharma research and development services. The company partners with biopharmaceutical firms including Moderna, AbbVie, and Genentech. It completed its Nasdaq IPO in June 2025 and competes in the molecular diagnostics and multi-cancer early detection markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CAI shares advanced from $15.38 to $24.58, a gain of roughly 59.8%. The move was concentrated in early August, when the stock jumped more than 20% in a single session following its second-quarter earnings report.
From roughly three months earlier, when shares closed near $15.94, the stock has risen about 54%. That rebound follows a steep decline from the 52-week high of $42.50, reached in 2025, to an intraday low of $14.19 in mid-May 2026. The recent 30-day surge represents the sharpest leg of a longer climb off the spring lows.
What Drove the 30-Day Rally
The main catalyst was the second-quarter 2026 earnings release on August 5, which triggered a one-day advance of more than 20%. Total revenue reached $263.7 million, up 45% year over year and ahead of consensus estimates, led by a 55% increase in molecular profiling services revenue to $252.3 million.
Clinical case volume rose to a record of roughly 59,200, up 18% year over year and 12% sequentially. GAAP gross margin expanded to 68% from 63% a year earlier, adjusted EBITDA increased to $55.7 million from $16.7 million, and the net loss narrowed to $0.6 million. Management raised full-year 2026 revenue guidance to a range of $1.03 billion to $1.04 billion, representing 27% to 28% growth.
Investor enthusiasm was also fueled by the launch of Caris Detect, a multi-cancer early detection blood test capable of screening for 58 cancer types from a single draw, along with the ChromoSeq and MI Clarity V2 assays. Management noted that Detect demand is running ahead of initial expectations and that the company is tripling related laboratory capacity, with a record blended average selling price above $3,850.
Quarterly Recovery Context
The quarterly picture reflects both the tail end of a selloff and the beginning of a recovery. Through the first half of 2026, shares traded well below their 2025 highs amid concerns about a January 2026 sales-force realignment and broader pressure on high-growth healthcare and diagnostic names. Institutional participation also softened earlier in the year.
The narrative began to shift as the company reported that its commercial reorganization, which expanded its territory structure from 82 to 146 territories, started paying off. Record case volume, margin expansion, a fifth consecutive quarter of positive adjusted EBITDA and free cash flow, and the Detect launch all pointed to re-accelerating growth. The August beat-and-raise quarter then crystallized that turnaround.
Key Factors to Monitor Going Forward
Looking ahead, investors are likely to monitor the commercial uptake of Caris Detect and whether demand can be supported by the expanded laboratory capacity without prolonged backorders. Reimbursement and regulatory milestones, including state approvals and MolDX technology assessments, will also matter, given that Detect currently operates on a self-pay basis.
Other factors include the ramp of ChromoSeq and MI Clarity V2, the planned launch of a minimal residual disease assay in the second half of 2026, and continued expansion of covered lives for Caris Assure. Management has signaled lower third-quarter EBITDA as it funds growth investments, so execution against raised full-year revenue guidance of $1.03 billion to $1.04 billion will be closely watched. Competitive dynamics in multi-cancer early detection may also influence sentiment. I’m watching this closely as execution on the new guidance will be telling.
AI Tools in My Research Process
When evaluating names like this, I often review automated strategies alongside fundamental data to gauge how different approaches are responding to recent catalysts. Tickeron’s AI Trading Bots provide a useful lens here, allowing me to see how various bot strategies have performed on healthcare and diagnostics stocks over comparable periods. The platform’s range of timeframes and risk parameters helps me cross-check my own observations without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CAI's RSI Oscillator is remaining in overbought zone for 3 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
CAI broke above its upper Bollinger Band on September 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on CAI as a result. In 25 of 32 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CAI just turned positive on September 16, 2026. Looking at past instances where CAI's MACD turned positive, the stock continued to rise in 7 of 10 cases over the following month. The odds of a continued upward trend are 70%.
Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAI advanced for three days, in 39 of 61 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 20 of 55 cases where CAI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 36%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.327) is normal, around the industry mean (25.929). P/E Ratio (3.129) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.178). CAI's Dividend Yield (0.021) is considerably higher than the industry average of (0.000). P/S Ratio (8.084) is also within normal values, averaging (437.043).
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the business of leasing international intermodal marine cargo containers
Industry Biotechnology
Advertisement